We receive many questions from people who are actively being treated for cancer and who have cancer but are not having active treatment asking if they should receive a COVID-19 vaccination. The American Society of Clinical Oncologists (ASCO), the largest oncology professional organization in the world has issued important guidelines about Cancer Thrivers and the question about their having a vaccine against the COVID virus.
ASCO’s bottom-line recommendation is that:
Cancer survivors may be offered vaccination against COVID-19 as long as any components of the vaccine are not contraindicated.
ASCO is saying that CANCER THRIVERS should consider having a vaccine, but they need to discuss with their doctors this recommendation and they need to confirm that there is not anything in the vaccine itself that would pose a potential danger to them.
The following webpage from ASCO ( https://www.asco.org/asco-coronavirus-resources/covid-19-patient-care-information/covid-19-vaccine-patients-cancer ) is quoted below:
On December 17, 2020, the American Society of Clinical Oncology and Infectious Diseases Society of America held a “COVID-19 Vaccine & Patients with Cancer” webinar to discuss the importance of COVID-19 vaccination and to provide expert opinion on its use for cancer patients. At the time of the webinar, there was only one vaccine authorized for use against COVID-19, the Pfizer/BioNTech vaccine, although the expert panel discussion focused on mRNA vaccines and addressed vaccines in general. The panel of oncology and infectious disease experts agreed that the Pfizer, and now Moderna, vaccines have been shown to be safe and effective for the general population and there was no evidence that they would not be safe for most cancer patients, although it should be noted that patients receiving immunosuppressive and cytotoxic treatments were excluded from participation in the vaccine trials to date so there is little to no data on the safety and efficacy of the Pfizer and Moderna vaccines in cancer patients.
Memorial Sloan Kettering Cancer Center has made available an interim guideline on vaccination for cancer patients. The recommendations in that guideline are based on opinion and extrapolation from other vaccine studies and may change rapidly as new information becomes available.
Should people with cancer be vaccinated against COVID-19?
At this time, patients with cancer may be offered vaccination against COVID-19 as long as components of that vaccine are not contraindicated. The current CDC interim clinical guidance discusses immunocompromised individuals. It states: “Immunocompromised individuals may still receive COVID-19 vaccination if they have no contraindications to vaccination. However, they should be counseled about the unknown vaccine safety profile and effectiveness in immunocompromised populations, as well as the potential for reduced immune responses and the need to continue to follow all current guidance to protect themselves against COVID-19.” The expert panel noted that while some immunocompromised patients may experience decreased response to the vaccine, it may still confer some benefit and is important to reduce the risk or severity of COVID-19 to cancer patients, especially given recent evidence of higher rates of severe infection. Further information on the vaccines can be found on the CDC website.
Should people undergoing active treatment for cancer be vaccinated against COVID-19?
At this time, patients undergoing treatment may be offered vaccination against COVID-19 as long as any components of the vaccine are not contraindicated. Oncologists have experience providing other types of vaccines to patients receiving treatment for cancer, including chemotherapy, immunotherapy, radiation therapy or stem cell transplantation. Strategies such as providing the vaccine in between cycles of therapy and after appropriate waiting periods for patients receiving stem cell transplants and immune globulin treatment can be used to reduce the risks while maintaining the efficacy of vaccination.
Should cancer survivors be vaccinated against COVID-19?
Cancer survivors may be offered vaccination against COVID-19 as long as any components of the vaccine are not contraindicated.
Are there people who should not be vaccinated?
At this time, only those with contraindications to a specific vaccine component should not be offered vaccination with that specific product. These contraindications are described in detail on the CDC’s vaccination clinical considerations page.
What other concerns are there for people with cancer who are vaccinated?
As there is still uncertainty around the extent to which immunocompromised patients with cancer will develop immunity in response to vaccination, vaccinated patients should continue to follow current guidance to protect themselves from exposure to COVID-19. The expert panel underscored the message that while providing the vaccine to cancer patients and their caregivers will reduce risk for infection or clinical COVID-19 disease, they emphasized the importance of continuing practices of wearing masks, social distancing, and maintaining good hand hygiene even after vaccination.
Other Information
· The ASCO/IDSA webinar was recorded and is available for listening.
ASCO will continue to work to provide accurate information regarding vaccination, see ASCO in Action.
Disclaimer
Answers to questions about COVID-19 published herein are provided by the American Society of Clinical Oncology, Inc. (“ASCO”) for voluntary, informational use by providers in the rapidly evolving novel coronavirus crisis. This information does not constitute medical or legal advice, is not intended for use in the diagnosis or treatment of individual conditions, does not endorse products or therapies, recommend or mandate any particular course of medical care, and is not a statement of the standard of care. New evidence may emerge between the time information is developed and when it is published or read. The information is not comprehensive or continually updated. This information is not intended to substitute for the independent professional judgment of the treating provider in the context of treating the individual patient. ASCO provides this information on an “as is” basis, and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions. Use of the information is subject to the complete ASCO website Terms of Use.
